Although the main bishydroxylated long-term metabolite of the WADA-banned anabolic agent ligandrol (LGD-4033) is an important metabolic marker, it is not readily available in sufficient quantities to facilitate the development and validation of related analytical protocols or sensors. A chemically more robust structure was postulated as an alternative to the one previously established. The NMR spectra of the synthesized material and its LC-HRMS comparison with a relevant metabolic sample support the proposed structural revision.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d2ob01907h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted Metabolic Investigation of Ligandrol and Analytical Methods Validation for Its Main Long-term Metabolite.
Chempluschem
May 2024
Institute of Nanoscience and Nanotechnology, National Centre for Scientific Research "DEMOKRITOS", P.O. Box 60037, Aghia Paraskevi, GR 153 10, Athens, Greece.
Prompted by the need for related analytical reference material in the frame of the fight against doping in sports, synthetic efforts towards the main long-term bishydroxylated metabolite (LGD-LTM1) of the nonsteroidal selective androgen receptor modulator (SARM) ligandrol have produced related derivatives that were exploited for a targeted metabolite analysis of urine samples obtained in the course of previous excretion studies of this SARM. Further clarifying ligandrol's metabolic profile, the availability of synthetic reference material permitted the structural elucidation of a previously reported pyrrolidinone-type metabolite and revealed its potential analytical utility as an additional long-term marker. Moreover, synthetic reference material enabled the comparison and validation of liquid chromatography coupled with mass spectrometry (LC-MS)-based and gas chromatography coupled with mass spectrometry (GC-MS)-based detection and identification methods focusing on the LGD-LTM1 marker.
View Article and Find Full Text PDFStructure revision and chemical synthesis of ligandrol's main bishydroxylated long-term metabolic marker.
Org Biomol Chem
November 2022
Cyprus Anti-Doping Authority, Makarion Athletic Centre Avenue, Engomi, CY 2400 Nicosia, Cyprus.
Although the main bishydroxylated long-term metabolite of the WADA-banned anabolic agent ligandrol (LGD-4033) is an important metabolic marker, it is not readily available in sufficient quantities to facilitate the development and validation of related analytical protocols or sensors. A chemically more robust structure was postulated as an alternative to the one previously established. The NMR spectra of the synthesized material and its LC-HRMS comparison with a relevant metabolic sample support the proposed structural revision.
View Article and Find Full Text PDFDetection of urinary arimistane metabolites in humans using liquid chromatography-mass spectrometry: Complementary results to gas chromatography mass spectrometric data and its application to antidoping analyses.
Rapid Commun Mass Spectrom
June 2021
Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo G. Onesti, 1, Rome, RM, 00197, Italy.
Rationale: The metabolism of arimistane (Arim) was first described in 2015, and androst-3,5-diene-7β-ol-17-one was proposed as the main metabolite excreted in urine. Recently, a more detailed study describing the findings in urine after the administration of Arim has been published. This study corroborated the previously described metabolite but also described several phase I and II metabolites, analyzing trimethylsilylated urinary extracts using accurate mass spectrometry coupled to gas chromatography (GC/qTOF).
View Article and Find Full Text PDFMass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Drug Test Anal
August 2016
Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Article Synopsis
- Elite sports face risks of drug misuse, prompting anti-doping authorities to consider and integrate potential performance-enhancing drugs like GSK1278863 into testing programs.
- GSK1278863, a hypoxia-inducible factor (HIF) inhibitor, can significantly improve oxygen transport by increasing red blood cell production, raising concerns about its abuse in sports.
- The study focuses on the mass spectrometric behavior of GSK1278863 and its metabolite for developing efficient urine testing methods to detect these substances in athlete samples.
Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing.
Rapid Commun Mass Spectrom
June 2015
Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Article Synopsis
- The text discusses the availability and analysis of LGD-4033, a synthetic anabolic agent (SARM), sold online, which could potentially enhance athletic performance.
- To analyze this substance and its metabolites, advanced techniques like nuclear magnetic resonance spectroscopy (NMR) and liquid chromatography/mass spectrometry (LC/ESI-HRMS) were used, revealing several products formed during metabolism.
- The study suggests that including LGD-4033 and its identified metabolites in doping tests could improve the effectiveness of current sports drug testing protocols.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!